Advanced Medical Solutions Group plc (AIM:AMS)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 542.52M |
| Revenue (ttm) | 228.94M |
| Net Income (ttm) | 9.95M |
| Shares Out | 216.14M |
| EPS (ttm) | 0.05 |
| PE Ratio | 55.53 |
| Forward PE | 19.36 |
| Dividend | 0.03 (1.14%) |
| Ex-Dividend Date | May 28, 2026 |
| Volume | 2,074,737 |
| Average Volume | 1,525,195 |
| Open | 247.50 |
| Previous Close | 251.00 |
| Day's Range | 247.50 - 252.00 |
| 52-Week Range | 175.00 - 272.00 |
| Beta | 0.63 |
| RSI | 69.83 |
| Earnings Date | Jun 16, 2026 |
About AIM:AMS
Advanced Medical Solutions Group plc, together with its subsidiaries, develops, manufactures, and distributes products for the surgical, woundcare, and wound-closure markets in the United Kingdom, Germany, rest of Europe, the United States, and internationally. The company operates in two segments, Surgical and Woundcare. It offers surgical products, such as tissue adhesives, sutures, haemostats, internal fixation devices, infection control, and internal sealants under LiquiBand, RESORBA, LiquiBandFix8, LIQUIFIX, and Seal-G, Vitalitec, and Acti... [Read more]
Financial Performance
In 2025, AIM:AMS's revenue was 228.94 million, an increase of 28.96% compared to the previous year's 177.52 million. Earnings were 9.95 million, an increase of 40.32%.
Financial StatementsNews
UK Stock Market News: Advance Medical Solutions, Kainos, Renishaw
Advanced Medical Solutions confirms bid interest, Kainos upgrades FY outlook as orders strengthen, profit and revenue upgrades at Renishaw
Bridgepoint weighs £550m bid for London-listed medical group AMS
The private equity backer of Burger King UK is weighing a takeover bid for Advanced Medical Solutions Group, a London-listed producer of surgical products.
Advanced Medical Solutions Group Earnings Call Transcript: H1 2025
Revenue grew 66% in H1 2025, driven by acquisitions and strong organic growth, with EBITDA up 42% and net debt reduced. Integration of Peters Surgical and Syntacoll is on track, supporting robust segment performance and a positive outlook for H2.